English 
Elix, Inc., a Japan-based AI drug discovery company, is pleased to announce that KYORIN Pharmaceutical
Co., Ltd. has adopted Elix DiscoveryTM, Elix’s proprietary AI-powered drug discovery platform.
In traditional drug development, researchers face the challenge of identifying promising compounds from
vast chemical libraries, which often results in prolonged research timelines, escalating R&D costs, and
low success rates. Against this backdrop, AI technologies are increasingly recognized for their potential to
streamline the drug discovery process and improve success probabilities. In particular, AI-driven
molecular design and compound profiling can enable the efficient generation of promising compounds,
accelerating the selection, synthesis, and evaluation processes.
Elix is a pioneering Japan-based AI drug discovery company on a mission to “Rethink Drug Discovery,”
partnering with pharmaceutical companies, universities, research institutions, and biotech startups. Its
flagship platform, Elix DiscoveryTM, launched in 2022, is built around the concept of “medicinal chemists
can truly use it” and is already in use by several leading pharmaceutical companies.
こちらもお読みください： Eisai’s Insomnia drug DAYVIGO approved for Use in China
Elix DiscoveryTM features an intuitive graphical user interface (GUI) that enables users to automatically
build predictive models for optimal compound profiling. Its powerful molecular generation capabilities
allow for the proposal of novel chemical structures beyond human imagination. Leveraging Elix’s
proprietary structure generation models, users can optimize predictive models and parameters directly
within the GUI, dramatically accelerating compound design. The platform supports both ligand-based
drug design (LBDD) and structure-based drug design (SBDD), incorporating tools like docking
simulations for a multi-faceted approach to drug discovery.
Beyond platform provision, Elix actively engages in collaborative research with its partners by combining
its advanced AI technologies with extensive domain expertise in drug discovery. In addition, Elix
DiscoveryTM also offers plans that include multiple AI models trained on datasets from 16 pharmaceutical
companies*3. Elix remains committed to advancing the creation of innovative drug candidates.
Comment from Junichi Ishiyama, Corporate Officer CSO, Senior Director of Discovery Research
HQs, KYORIN
We are dedicated to creating highly valuable new drugs that address unmet medical needs. We actively
collaborate with external institutions and utilize innovative external technologies, taking on the challenge
of “drug discovery innovation” through these research activities. We expect that the implementation of
Elix DiscoveryTM will accelerate our research and enhance its quality by integrating our drug discovery
capabilities with AI-driven drug discovery, ultimately enabling us to create highly valuable new drugs.
Comment from Shinya Yuki, CEO of Elix
We are deeply honored that KYORIN has chosen to adopt our AI drug discovery platform, Elix
DiscoveryTM. Developed under the concept of “medicinal chemists can truly use it,” the platform is
designed to maximize researchers’ capabilities. By combining KYORIN’s long-standing expertise in drug
discovery with our cutting-edge AI technology, we are confident this collaboration will accelerate drug
discovery research. We look forward to shaping the future of the field together.
日本語